Kristian Helin
VietnamexecutiveMale9.0Global Dominance: 0.00%Professor Kristian Helin is the chief executive of the Institute of Cancer Research in London and a leading figure in cancer research. He has recently been in the news for discussing the promising results of a clinical trial that showed immunotherapy, specifically pembrolizumab, can double the time patients with head and neck cancer remain free from evidence of the disease. His insights highlight the transformative potential of immunotherapy in cancer treatment.
Country presence
Recent news mentions
Kristian Helin, the CEO of ICR, affirmed that the injection represents a significant advancement in modern medicine.
Thuốc tiêm mới có thể xóa sổ khối u ung thư giai đoạn cuốiVietnam· 2026-06-01
Professor Kristian Helin is the CEO of the Institute of Cancer Research and commented on the significant advancements in treatment.
Index - Tech-Tudomány - Orvosi áttörés: egy új rákellenes injekció 15 végstádiumú betegnél teljesen eltüntette a daganatot
Hungary· 2026-05-31Professor Kristian Helin is the executive director of the Institute of Cancer Research.
Tratament împotriva cancerului cu rezultate fără precedent: injecția care poate elimina complet tumorile
Romania· 2026-05-31Prof Kristian Helin, chief executive of the ICR, emphasized the significance of the study in developing new cancer treatments.
Cancer jab can eradicate entire tumours in patients, trial shows – The Irish Times
Ireland· 2026-05-30Prof Kristian Helin, the chief executive of the ICR, emphasized the significance of the study in developing new cancer treatments.
Cancer jab can eradicate entire tumours in patients, trial shows | Cancer research
United Kingdom· 2026-05-30Prof Kristian Helin, the chief executive of the Institute of Cancer Research, said: 'Immunotherapy continues to deliver ...'
‘Gift of life’: experts hail neck and head cancer breakthrough | CancerUnited Kingdom· 2025-05-31
